DUBLIN, Ireland and MELBOURNE, Australia, May 7, 2015 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapy developer, today announced that Dr. Mark Heffernan, Nexvet's Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2015 Health Care Conference in Las Vegas on Thursday, May 14, 2015 at 12:00PM PDT.
Dr. Heffernan will provide an overview of Nexvet's pioneering developments in the field of companion animal biologic therapies, including 100% species-specific monoclonal antibody therapies for chronic conditions.
The presentation will be available on the investor section of Nexvet's website at http://ir.nexvet.com for 30 days following the completion of the event.
About Nexvet (www.nexvet.com)
Nexvet is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet's proprietary PETization™ platform is designed to rapidly create monoclonal antibodies ("mAbs") that are recognized as "self" or "native" by an animal's immune system, a property Nexvet refers to as "100% species-specificity." Nexvet's product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.